Table 2 Demographic and clinical characteristics of the proliferative diabetic retinopathy (PDR) groups at baseline.

From: Levosulpiride for the treatment of diabetic macular oedema: a phase 2 randomized clinical trial

 

Placebo (n = 18)

Levosulpiride (n = 18)

p

Age years (SD)

57.6 (6.4)

56.2 (8.6)

0.58a

Sex F n (%)

10 (55.6)

9 (50)

0.73b

BMI (kg/m2) (SD)

28.2 (5.1)

28.5 (9.4)

0.42c

DM2 years (SD)

15.8 (5.9)

16.0 (6.3)

0.92a

HbA1c, % (SD)

7.5 (1.4)

8.0 (1.9)

0.42a

SCr mg/dl (SD)

1.2 (0.5)

1.0 (0.4)

0.27c

eGFR ml/min) (SD)

69.9 (24.8)

83.8 (27.4)

0.12a

SPRL ng/ml (SD)

7.7 (4.0)

10.3 (5.7)

0.10c

  1. All patients were with PDR before undergoing elective pars plana vitrectomy and oral treatment with placebo or levosulpiride. Values are means. Number of patients (n).
  2. BMI body mass index, DM2 type 2 diabetes mellitus, HbA1c glycosylated haemoglobin, SCr serum creatinine, eGFR estimated glomerular filtration rate (CKD-EPI equation), SPRL serum PRL.
  3. p values vs. placebo based on Students t testa, chi-square testb, and Mann–Whitney U testc.